Phase 2 N=7 Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients
End Stage Renal Disease
Primary: Mean Maximum Concentration (Cmax) of Ertapenem in Hemodialysis Patients — 663.1 mcg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Clinical Study of the Endotracheal Tube Used in Prone Position Ventilation Condition
Mechanical Ventilation Complication
Primary: Displacement of the Endotracheal Tube — 0; 22; 0; 11 Participants — p=<0.05
N/A N=1 Using the Xbox Kinect for Chronic TBI
Traumatic Brain Injury
Primary: Dynamic Gait Index (DGI) — 12; 17; 19 units on a scale
Phase 2 N=30 Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Thalassemia Major
Primary: Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC) — -5.934 % change of hematocrit-adjusted volume
Phase 2 N=209 A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
Mild Cognitive Impairment · Dementia
Primary: Conversion From Mild Cognitive Impairment to Alzheimer's Disease Compared to Placebo — 14; 21 Participants — p=<0.16
Phase 1 N=15 Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
Neoplasm
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 1 N=879 Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Asthma
Primary: Area Under the Serial FEV1-time Curve (AUC 0-12h) — 29.610; 30.151; 27.270 Liters — p=<0.05
N/A N=16 Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L
Smoking
Primary: Maximum Concentration (Cmax) of Nicotine Following Single Use of Nicorette® Inhalator — 6.095 ng/mL
N/A N=71 Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy
CRC
Primary: Mean Score of Boston Bowel Preparation Scale (BBPS) Index Prior and After the Use of MotusGI CleanUp System — 2.9; 2.9 units on a scale
N/A N=52 Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
Intellectual Disability · Autism · Multiple Congenital Anomalies
Primary: Satisfaction With Genomic Test Report — 0; 2; 1; 1 Participants
Phase 4 N=13 Effect of Valproic Acid Concentration on Photic Response
Photosensitive Epilepsy
Primary: Difference in SPR During Placebo and VPA Infusions — 15.917; 14.609 standard photosensitive range (SPR) — p=0.016
Phase 3 N=44 Proton/Photon Rt - Benign Meningiomas(P92-13)
Benign Meningioma
Primary: Progression Free Survival — 91; 91; 86; 81 percentage of participants surviving — p=0.234
N/A N=496 Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography
Breast Cancer
Primary: Detection of Breast Cancer (Sensitivity)
Phase 2 N=7 Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Hodgkin Disease · Hodgkin's Lymphoma · Lymphoma
Primary: Dose-limiting Toxicity of Gemcitabine Due to Non-hematologic Toxicity — 0; 3 participants
Phase 2 N=23 Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
Fatty Liver Disease, Nonalcoholic · Nonalcoholic Steatohepatitis · Lipodystrophy
Primary: Liver Histopathology — 6; 5 units on a scale